NAFLD/MASLD

Clinical trials for NAFLD/MASLD explained in plain language.

Never miss a new study

Get alerted when new NAFLD/MASLD trials appear

Sign up with your email to follow new studies for NAFLD/MASLD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for fatty liver: phase 3 drug trial targets scarring

Disease control Ongoing

This study tests a drug called efruxifermin against a placebo in 700 adults with fatty liver disease (NASH/MASH). The goal is to see if the drug is safe and can reduce liver scarring. Participants must have signs of metabolic syndrome or type 2 diabetes and a confirmed liver diag…

Matched conditions: NAFLD/MASLD

Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control

Last updated May 26, 2026 12:10 UTC

NAFLD/MASLD

Get alerted when new NAFLD/MASLD trials appear

New hope for fatty liver: phase 3 drug trial targets scarring